Evidence map›Paper›PMID 24492489›Full record

ArticleProstate cancer and prostatic diseases2014

Genetic variants in the CYP24A1 gene are associated with prostate cancer risk and aggressiveness in a Korean study population.

J J Oh, S-S Byun, S E Lee, S K Hong, C W Jeong, W S Choi, D Kim, H J Kim, S C Myung

Abstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

J J Oh1] CHA Bundang Medical Center, Department of Urology, CHA University, Seongnam, Korea [2] CHA Cancer Research Center, CHA University, Seoul, Korea.
S-S ByunDepartment of Urology, Seoul National University Bundang Hospital, Seongnam-si, Korea.
S E LeeDepartment of Urology, Seoul National University Bundang Hospital, Seongnam-si, Korea.
S K HongDepartment of Urology, Seoul National University Bundang Hospital, Seongnam-si, Korea.
C W JeongDepartment of Urology, Seoul National University Bundang Hospital, Seongnam-si, Korea.
W S ChoiChoi Won Suk Urology Clinic, Youngin, Korea.
D KimDepartment of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA, USA.
H J Kim1] Advanced Urogenital Disease Research Center, Chung-Ang University College of Medicine, Seoul, Korea [2] Research Institute for Translational System Biomics, Chung-Ang University College of Medicine, Seoul, Korea.
S C Myung1] Advanced Urogenital Disease Research Center, Chung-Ang University College of Medicine, Seoul, Korea [2] Research Institute for Translational System Biomics, Chung-Ang University College of Medicine, Seoul, Korea [3] Department of Urology, Chung-Ang University College of Medicine, Seoul, Korea.
Seoul National University Bundang Hospital · KRChung-Ang University · KRCHA University Bundang Medical Center · KRPennsylvania State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVitamin D-deactivating enzyme CYP24A1 had controversial effects on prostate cancer risk; the genetic study also showed the controversial results. Therefore, we identified the relationships between polymorphisms in CYP24A1 and prostate cancer in a Korean cohort.

methodsWe evaluated the association between 21 single-nucleotide polymorphisms (SNPs) in the CYP24A1 and prostate cancer in Korean men (272 prostate cancers and 173 controls). BPH patients with high PSA or abnormal digital rectal examination who underwent negative prostate biopsy were enrolled in the control group. Twenty-one SNPs in the CYP24A1 were selected from the International HapMap database and the NCBI database with calculation of minor allele frequency and linkage disequilibrium, preferably including the SNPs that were nonsynonymous and located within exons. We also investigated the association between 21 SNPs in the CYP24A1 gene and known clinical characteristics, such as the PSA level, clinical stage, pathological stage and Gleason score.

resultsThe statistical analysis suggested that five CYP24A1 sequence variants (rs2248461-odds ratio (OR): 0.63, rs2248359-OR: 0.65, rs6022999-OR: 0.65, rs2585428-OR: 0.46, rs4809959-OR: 0.52) had a significant association with prostate cancer risk after multiple comparisons by a method of false discovery rate. Logistic analyses of the CYP24A1 polymorphisms with several prostate cancer-related factors showed that several SNPs were significant: four SNPs to PSA level, three to clinical stage, two to pathological stage and two SNPs to the Gleason score.

conclusionsThe results of this study suggest that some CYP24A1 gene polymorphisms might be associated with the risk of prostate cancer in Korean men. Five CYP24A1 sequence variants showed the significance to predict prostate cancer, and several SNPs of CYP24A1 gene had an important finding to predict prostate cancer-related factors. However, these results should be validated in future large-scale studies.

Indexed as

AgedAsian PeopleCase-Control StudiesGene FrequencyGenetic Predisposition to DiseaseGenotypeHumansKallikreinsLinkage DisequilibriumMalePolymorphism, Single NucleotideProstate-Specific AntigenProstatic NeoplasmsRiskRisk FactorsVitamin D3 24-HydroxylaseCYP24A1 protein, humanKallikreinsKLK3 protein, humanProstate-Specific AntigenVitamin D3 24-Hydroxylase

Identifiers

PMID24492489
OpenAlexW1976216662

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.